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Dominant optic neuropathies causing fiber loss in the optic nerve are among
the most frequent inherited mitochondrial diseases. In most genetically resolved
cases, the disease is associated to a mutation in OPA1, which encodes an inner
mitochondrial dynamin involved in network fusion, cristae structure and mitochondrial
genome maintenance. OPA1 cleavage is regulated by two m-AAA proteases, SPG7
and AFG3L2, which are, respectively involved in Spastic Paraplegia 7 and Spino-
Cerebellar Ataxia 28. Here, we identified a novel mutation c.1402C>T in AFG3L2,
modifying the arginine 468 in cysteine in an evolutionary highly conserved arginine-
finger motif, in a family with optic atrophy and mild intellectual disability. Ophthalmic
examinations disclosed a loss of retinal nerve fibers on the temporal and nasal sides
of the optic disk and a red–green dyschromatopsia. Thus, our results suggest that
neuro-ophthalmological symptom as optic atrophy might be associated with AFG3L2
mutations, and should prompt the screening of this gene in patients with isolated and
syndromic inherited optic neuropathies.
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INTRODUCTION
Dominant optic atrophy (DOA) is a neurodegenerative disease that primarily targets the retinal
ganglion cell (RGC), representing an important cause of early onset blindness. Inmost patients, the
clinical presentation is restricted to visual impairment, but in about 20% of them, other symptoms
are associated such as deafness, muscle weakness, and peripheral neuropathy (Yu-Wai-Man et al.,
2010; Lenaers et al., 2012; Maresca et al., 2013). DOA is caused by mutations mostly in OPA1
(Alexander et al., 2000; Delettre et al., 2000; Ferre et al., 2015) and rarely in OPA3 (Reynier
et al., 2004) or SPG7 (Klebe et al., 2012), all encoding mitochondrial inner membrane proteins.
In some cases, DOA associated to deafness is caused by WFS1 mutations (Rendtorﬀ et al., 2011),
encoding an endoplasmic reticulum protein, regulating calcium homeostasis and consequently
mitochondrial physiology. Nevertheless, the systematic screening by Sanger sequencing of exonic
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sequences in OPA1, OPA3, and WFS1 genes in our DOA
cohort only allowed for about 50% of genetic diagnoses. We
further excluded OPA1 deletion/duplication in all patients, by
multiplex ligation-dependent probe ampliﬁcation (SALSAMLPA
KIT P229-B1 OPA1 –MRC-Holland), except one, who presented
a full OPA1 deletion.
Thus, to deepen DOA genetic diagnosis, we performed whole
exome sequencing (WES) on the proband from 12 unresolved
DOA families. We report here the results obtained for one
family, presenting an Optic Atrophy and mild intellectual
disability (Figure 1A). Amongst the 60,000 variants identiﬁed
by WES on the index patient III.4, no mutation was found
in OPA1, OPA3, and WFS1 genes, that were covered by a
minimal sequencing depth of 50x, 44x, and 40x, respectively.
We also carefully excluded mutations in eleven genes (AIFM1,
ATP1A3, c12orf65, CISD2, FXN, MTPAP, PRPS1, SFXN4, SPG7,
TIMM8, and TSFM), for which mutations might cause clinical
presentations related to our patients (e.g., Mohr-Tranebjaerg
and CAPOS syndromes). Thus, we progressively ﬁltered WES
data. After excluding intronic, 5′UTR, 3′UTR and synonymous
variants, we obtained 14,241 exonic and splicing variants. A total
of 9,776 variants were selected with a number of call higher
than 4 using the GATK, VarScan, SNVer, Lofreq, Platypus
softwares. We discarded common variants reported in NHLBI
Exome Sequencing Project, Exome Variant Server, NCBI, the
1000 genomes and ExAC ver0.2, with a frequency greater
than 1%, leading to 145 left variants. Then 30 deleterious
SNPs predicted by SIFT, PolyPhen-2, and Mutation Taster
softwares were retained (see Supplementary Table S1). Finally,
these variants were ﬁltered for heterozygous mutations in gene
encoding mitochondrial protein (MitoCarta), as to date all DOA
genes are involved in mitochondrial physiology. We only found
the c.1402C>T heterozygous mutation in AFG3L2 exon 11
(Figure 1B) that was never reported before in any database (see
above for a list). It modiﬁes an evolutionary highly conserved
arginine 468 in cysteine (p.Arg468Cys) within an arginine-ﬁnger
motif (RPGRxxR) that is found in the AAAdomain of all AFG3L2
orthologs and SPG7 paralogs. The arginine 468 is also conserved
in the prokaryote FtsH from E. coli (Figure 1C). In silico
prediction of the p.Arg468Cys pathogenicity by Polyphen2, SIFT,
Mutation taster, imutant, Pmut, MetaSVM, MetaLR, FathMM,
and PhD-SNP programs gave the highest scores, supporting the
pathogenicity of this mutation.
Patient II.4
This 48-year-old male complained of visual diﬃculties since
12 years of age including decrease in visual acuity, photophobia,
and color vision impairment with very slow progression of
visual loss. He otherwise had normal development without
neuromuscular or other sensory involvement, but he had mild
intellectual disability. His best corrected visual acuity was
decreased to 0.3 and 0.4 in the right and left eyes, respectively.
Fundus examination revealed bilateral moderate optic disk pallor
(Figure 2A, top), and optical coherence tomography (OCT)
disclosed a moderate overall decrease in the thickness of the
retinal nerve ﬁber layer (Figure 2B, top). Color vision testing
showed a red/green axis of dyschromatopsia and visual ﬁeld
indicated a decrease in light sensitivity without scotoma (not
shown). He refused further neurological examination and MRI
scanning.
Patient III.4
His son was born after a normal pregnancy and delivery was
uneventful. Motor development was normal, he managed
to walk unaided at 14 months. Learning diﬃculties were
noticed in primary school. Cognitive evaluation disclosed a
moderate intellectual disability (Wechsler Intelligence Scale
III: Total Intellectual Quotient 47) and the patient beneﬁted
of a special educational program from the age of 8, and was
admitted in an institution for patients with mental impairment
from the age of 14. This patient had no clinical complaint
especially no unsteadiness, no clumsiness, no cramping,
no fatigability. Clinical examination was performed at the
age of 18 and disclosed a discrete Kyphosis, while motor
strength, sensory evaluation, osteotendinous reﬂexes and
cranial motor nerve functions were normal. Oculomotor
movements were normal. The patient did not exhibit any
sign of stato-kinetic ataxia; his family never noticed any
jerk, and clinical examination did not disclose myoclonias.
Audiological assessment including tonal and vocal audiometry
was normal.
Ophthalmological investigations disclosed a best corrected
visual acuity of 0.5 on both eyes, with diﬃculties to ﬁxate his
gaze. Fundus examination revealed bilateral severe optic disk
pallor (Figure 2A, bottom) and OCT examination disclosed a
marked overall decrease in the thickness of the retinal nerve
ﬁber layer (Figure 2B, bottom). His brain MRI disclosed reduced
size of the optic tract (Figure 3A, left) and atrophy of the optic
chiasma (Figure 3A, right), without any sign of cerebellar atrophy
(Figure 3B, left and right). MRI spectroscopy was normal.
Both patients denied to do further examination, therefore skin
biopsy and brain MRI of the father were not available. The other
family members were not compliant with clinical and genetic
analysis.
BACKGROUND
The AFG3L2 and SPG7 m-AAA proteases have crucial multiple
functions in the homeostasis of mitochondrial protein synthesis,
assembly and degradation. On the one hand, homo and hetero-
polymers of these proteases have broad functional targets, as
for example proteins involved in the assembly of ribosomes
and respiratory chain complexes, the degradation of misfolded
proteins and the maintenance of mitochondrial nucleoids. On the
other hand, they have also highly speciﬁc targets as the proteolytic
cleavage of MRLP32 and OPA1 (Martinelli and Rugarli, 2010).
The latter cleavage in OPA1 amino-terminal region is required
for the physiological equilibrium between pro-fusion and pro-
ﬁssion isoforms of this large GTPase (Ehses et al., 2009).
In this respect, AFG3L2 down-regulation aﬀects respiratory
capacity and calcium uptake, and induces mitochondrial network
fragmentation (Maltecca et al., 2012), a cellular phenotype
that we also found in cell lines with altered OPA1 expression
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FIGURE 1 | Identification of AFG3L2 mutation. (A) Pedigree showing the family with the affected members in black, and the segregation of the p.Arg468Cys
amino-acid change in the two affected patients, knowing that DNA sample was not available for the other family members. (B) Electrophoregram presenting the
AFG3L2 c.1402C>T heterozygous mutation. (C) Alignment of AFG3L2 orthologs (amino-acids 460 to 476) showing the evolutionary conserved positions around the
Arginine 468, which is squared in red in the triple arginine motif (bold rectangles). (H.s. Homo sapiens; D.r. Danio rerio; X.l. Xenopus laevis; D.m. Drosophila
melanogaster; A.t. Arabidopsis thaliana; E.c. Escherichia coli FtsH protein; SPG7: human paralog of AFG3L2).
(Olichon et al., 2007; Chevrollier et al., 2008; Dayanithi et al.,
2010). The possible consequences of AFG3L2 mutation might
be related to the pathophysiology of DOA, a disease which
FIGURE 2 | Ophthalmological exploration of AFG3L2 patients. (A) Eye
fundus (RE: right eye; LE: left eye) from patient II.4 (top) and patient III.4
(bottom) disclose temporal pallor of the optic disks. (B) Optical Coherence
Tomography scanning and measurement of the retinal nerve fiber layers of the
optic disks evidenced a drastic thickness reduction in the temporal and nasal
quadrants of patient II.4 (top) and III.4 (bottom).
is caused by OPA1 haplo-insuﬃciency or eventually by a
dominant negative process (Olichon et al., 2007). Thus, the
p.Arg468Cys mutation might aﬀect AFG3L2 speciﬁc interaction
with OPA1 long isoform and consequently its processing, leading
to a bias in OPA1 physiological maturation and pro-fusion
activity.
To date, three genes have been identiﬁed as responsible
for non-syndromic DOA: OPA1, OPA3, and SPG7 (Alexander
et al., 2000; Delettre et al., 2000; Reynier et al., 2004;
Klebe et al., 2012), encoding proteins embedded in the inner
mitochondrial membrane (Olichon et al., 2002; Atorino et al.,
2003; Grau et al., 2013), and involved directly or indirectly
in mitochondrial fusion and ﬁssion (Olichon et al., 2003;
Ishihara et al., 2006; Ryu et al., 2010). OPA1 mutations
are by far the most frequently found in patients with non-
syndromic DOA, and to date more than 250 mutations
have been identiﬁed in this gene (Ferre et al., 2015). Three
and one dominant mutations were respectively identiﬁed in
OPA3 and SPG7 genes. In virtually all cases, patients show
optic disk atrophy with a predominant loss of the temporal
retinal nerve ﬁber bundle revealed by OCT examination (Klebe
et al., 2012; Lenaers et al., 2012). Nevertheless, it should
be stressed that DOA is frequently associated to secondary
symptoms, most often neurosensory deafness (Amati-Bonneau
et al., 2005), but also external ophthalmoplegia, myopathy,
peripheral neuropathy, ataxia, and spastic paraplegia for OPA1
patients (Yu-Wai-Man et al., 2010), and cataract, postural tremor,
extrapyramidal signs, ataxia, areﬂexia, and neurosensory deafness
for OPA3 patients (Reynier et al., 2004; Ayrignac et al., 2012;
Grau et al., 2013). Concerning SPG7, most recessive patients
with primary spastic paraplegia also present optic atrophy,
whereas in the single family reported with a dominant SPG7
mutation, patients had isolated optic atrophy (Klebe et al.,
2012).
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FIGURE 3 | Brain MRI of patient III.4 at 18 years of age. (A) Left: Frontal
section, T2 sequence, showing atrophy of the optic nerve (arrow) and Right:
reduced size of the chiasma (arrow). Magnification of the optic track (Left) and
chiasma (Right) regions are shown underneath the full picture. (B) Left: Sagittal
section, T1 sequence, showing a normal aspect of the brain, especially of the
vermis (arrow); Right: axial section, T2 sequence, showing a normal aspect of
the posterior fossa, especially the cerebellar hemisphere (arrow).
Importantly, combined optic nerve atrophy and
encephalopathy were not previously reported in families
with dominant inheritance, whereas this is encountered in
syndromic recessive forms of optic atrophy (Metodiev et al.,
2014). Thus the clinical presentation that we report here is
somehow particular in associating DOA to mild intellectual
disability.
Mutations in AFG3L2 are responsible for the SCA28 and
SPAX5 forms of spinocerebellar ataxia (Di Bella et al., 2010;
Pierson et al., 2011). In SCA28, most cases are caused by
heterozygous mutations in exon 15 and 16, with a single
exception (c.1295A>C, p.N432T) in exon 10 (Cagnoli et al.,
2010; Di Bella et al., 2010), whereas in SPAX5, two families were
reported with homozygous mutations in exon 15 (c.1847A>G,
p.Y616C and c.1875G>A, p.M625I; Pierson et al., 2011; Muona
et al., 2015), (Figure 4). Functional studies of the encoded m-
AAA protease with mutation in exons 15 or 16 revealed an
abnormal C-terminus M41 peptidase domain compromising the
stability and proteolytic activity of them-AAA complex, possibly
through a dominant negative process. By contrast, the exon 10
mutation modiﬁes the structure of the pore channel entry, in
which substrates are pulled to be degraded (Di Bella et al., 2010).
In addition, two AFG3L2 gene deletions have been reported in
SCA28 patients, one of the entire gene (Myers et al., 2014),
and one including exon 14 to exon 16 (Smets et al., 2014),
as well as one frame shift mutation in exon 15, deleting the
last 144 amino acids (Musova et al., 2014), (Figure 4). Thus
AFG3L2 haplo-insuﬃciency is one of the possible causes of
SCA28. Very recently, a novel c.346A>G, p.G116R mutation
in the N-terminal domain of AFG3L2 protein was reported in
a patient presenting spontaneous myoclonus at proximal limb
associated to pyramidal signs. As for the cases we report here,
this young patient did not present cerebellar ataxia, oculomotor
abnormalities or sensory deﬁcits (Mancini et al., 2015), although
we cannot exclude that they will develop these symptoms later in
life.
In both SCA28 and SPAX5 presentations, the patients
have a typical cerebellar syndrome with ataxia, dysarthria,
and oculomotor apraxia, variously associated with pyramidal
and muscular signs, eventually including ptosis and external
ophthalmoplegia (Cagnoli et al., 2010; Di Bella et al., 2010;
Pierson et al., 2011). In none of them, optic atrophy, cognitive
FIGURE 4 | Localization of AFG3L2 mutations in the gene and protein. The structures of AFG3L2 gene (17 exons) and the protein (domains and amino-acid
positions) are described on the top and bottom of the figure, respectively, with all the pathogenic mutations and associated clinical presentation reported to date. In
black: SCA28, in blue: SPAX5, in green: Myoclony and pyramidal signs, in red: present case.
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deﬁcit or intellectual disability has ever been reported. Yet, optic
atrophy is found associated with spastic paraplegia linked to
recessive mutations in SPG7, the paralog of AFG3L2 encoding
another component of the m-AAA protease involved in OPA1
proteolytic maturation (Casari et al., 1998; Arnoldi et al., 2008).
In addition, genetic analysis of a large family with isolated optic
atrophy disclosed the ﬁrst dominant SPG7mutation, c.1232A>C,
p.D411A, aﬀecting the AAA domain (Klebe et al., 2012), 56
amino-acids upstream of the conserved RPGR motif, in which
we found the AFG3L2 mutation.
DISCUSSION
Both patients described in this study, who harbored a novel
AFG3L2 mutation, had typical signs of hereditary optic atrophy,
without abnormal gait or signs of cerebellar impairment. Indeed,
they complained of bilateral, symmetrical visual loss starting
in infancy and they showed optic disk pallor with thinned
retinal nerve ﬁber layer. Dyschromatopsia was also present in
one of the patient. This is in contrast with the SCA28 and
SPAX5 presentations in which optic atrophy has never been
reported. Yet, it is possible that asymptomatic optic atrophy
exists in SCA28 and SPAX5 patients since decreased visual
acuity can be absent in moderate forms of optic atrophy,
suggesting that future patients with AFG3L2 mutations should
have systematic fundus and OCT examinations. Although
the cases we report here do not present the spinocerebellar
ataxia typical of SCA28 patients, we cannot rule out the
possibility that they will develop this symptom later in their life
time.
Finally, both patients showed mild mental retardation,
a ﬁnding which has not yet been associated to DOA,
SCA28, or SPAX5. Whether cognitive disturbances is related
to the AFG3L2 mutation itself, or to an independent
phenomenon related to another dominant locus segregating
separately from AFG3L2 was not determined. Therefore,
a fortuitous association of DOA and mental deﬁciency
in these patients cannot be ruled out. Nevertheless,
we suggest that genetically unresolved DOA patients
with or without intellectual disability could be screened
for the presence of an AFG3L2 mutation. In this
respect, ﬁnding novel AFG3L2 mutations related to
DOA or disclosing optic atrophy in SCA28 patients
would strongly reinforce the data that we presented
here.
CONCLUDING REMARKS
Dominant Optic Atrophy is among the most frequent
mitochondrial disorder and probably the most frequent form
of inherited optic neuropathy (Lenaers et al., 2012) and
essentially associated to an OPA1 mutation. Nevertheless
exonic sequencing of this gene and OPA3 and SPG7, the
other known DOA genes, only leads to some 50% of positive
results. Therefore, identiﬁcation of additional genes involved
in DOA is required to help genetic diagnosis. In this respect,
the identiﬁcation of a dominant mutation in SPG7 and
eventually in AFG3L2 in DOA patients suggests that m-
AAA proteases could be involved in a pathway responsible
of retinal ganglion neuron degeneration, and contribute
to a better understanding of the etiology and genotype –
phenotype correlations of inherited diseases aﬀecting the
optic nerve. Although probably very uncommon, the possible
involvement of AFG3L2 and SPG7 in optic neuropathies
should prompt the screening of these genes in isolated and
syndromic DOA patients, negative for OPA1 and OPA3
mutation. They also should favor neuro-ophthalmological
examinations in SCA28 and SPAX5 patients with spinocerebellar
ataxia.
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